ClinicalTrials.gg
RecruitingNCT07403058R-HFrEFUpdated Nov 6, 2026

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects With Reduced Ejection Fraction

An interventional study of Right Greater Splanchnic Nerve (GSN) ablation and Sham Control in Heart Failure With Reduced Ejection Fraction (HFrEF), sponsored by Axon Therapies, Inc.. Recruiting at 9 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Axon Therapies, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 6, 2026Now RecruitingFirst site in Georgia+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 342 studies in Heart Failure with a site in Spain — 76 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Spain.

Planned enrollment
235th of 263
50 · median 294
Started
2026
with 21 others
No phase
119 of 342
34 open now
Primary completion
2028-03
later than 66 of 98 live
Registered
327th of 342
by date

Among the 342 studies in Heart Failure with a site in Spain, this one is the 235th largest by planned enrollment of the 263 interventional ones that give a count, is one of 22 that started in 2026, is one of 119 with no phase, reaches primary completion later than 66 of the 98 other live ones, and was the 327th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

76 of the 342 studies in Heart Failure with a site in Spain are open now. Recruiting first, the newest first:

70 more — sign in →

All 76 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Heart Failure with a site in Spain, or all of them as a file.
02

Study summary

This study is a small, early-stage clinical trial designed to test whether a new catheter-based procedure is safe and may help people with heart failure with reduced ejection fraction (HFrEF). The procedure uses the Satera Ablation System to treat the right greater splanchnic nerve, which may play a role in heart failure symptoms. The study also aims to identify which types of patients might benefit most from this treatment in the future.

Up to 50 patients aged 40 or older with HFrEF will take part at as many as 10 hospitals worldwide. The study is prospective, meaning patients are followed forward in time, and it is randomized, double-blinded, and sham-controlled. Patients are randomly assigned in a 2:1 ratio to either receive the actual nerve ablation treatment or a sham (placebo) procedure. Randomization happens during the procedure, after anesthesia or sedation, to reduce the risk of revealing which treatment the patient receives.

Neither the patient nor their heart failure doctor will know whether the patient received the real treatment or the sham. However, the doctor performing the procedure and certain study staff will know, mainly for safety and operational reasons.

The sham procedure is designed to mimic the real procedure as closely as possible without performing the nerve ablation. It involves placing a small needle in the groin or neck and accessing the vein, but no treatment catheter is inserted. The sham procedure takes about the same amount of time as the real treatment (around 45 minutes) to help account for any placebo effect.

Overall, this study is focused on evaluating safety and early signs of benefit rather than proving long-term effectiveness.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction (HFrEF)

Browse trials for

Keywords

  • Heart Failure
  • Reduced Ejection Fraction
  • Right Greater Splanchnic Nerve (GSN)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chronic heart failure, defined as:

    1. Symptoms of HF requiring current (QD or QOD or appropriate dosing as per screening committee) treatment with loop diuretics for at least 30 days prior to screening visit, AND
    2. class II, NYHA class III, or ambulatory NYHA class IV symptoms at screening or signs of HF, AND
    3. NT-proBNP >800 pg/ml in normal sinus rhythm (>1400 pg/ml in atrial fibrillation or flutter) within 3 months of consent, with no adjustment for
  2. Ongoing stable GDMT HF management for a minimum of 30 days prior to screening (unless unable to tolerate GDMT) which refers to those HF drugs carrying a Class I indication, including:

    1. An inhibitor of the renin-angiotensin system (RAS inhibitor), including an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI) and beta-blocker (BB).
    2. A mineralocorticoid receptor antagonist (MRA), Sodium-Glucose Transport 2 inhibitor (SGLT2i), or nitrates/hydralazine, should be used in appropriate patients, according to the published guidelines unless intolerant or not indicated.
    3. Drug intolerance, , or lack of indications must be attested to by the investigator. Patients should be on appropriate doses of diuretics as required for volume control.
    4. Stable GDMT refers to consistent dose (change is considered a more than 100% increase or 50% decrease in dose) for at least 30 days prior to screening visit or as appropriate per the screening committee.
  3. Participants cannot have started a glucagon-like peptide (GLP)-1 or gastric inhibitory peptide (GIP) agonist within the last 6 months or plan to start a GLP-1 or GIP agonist within the ensuing 6 months after enrollment.
  4. Considered for Class I recommended cardiac rhythm management device therapy. Specifically: if indicated by class I guidelines, cardiac resynchronization therapy (CRT), an implanted cardioverter- defibrillator (ICD) or a pacemaker should be implanted at least 3 months prior to enrollment. These criteria may be waived if a patient is clinically contraindicated for these therapies or refuses them and must be attested to by the investigator.
  5. 20% - 40% (at screening visit and determined by echo core lab).
  6. Age ≥40 years.
  7. Subject is willing and able to provide appropriate study-specific , follow protocol procedures, and comply with follow-up visit requirements.

Exclusion criteria

Exclusion Criteria:

  1. MI (type I) and/or percutaneous cardiac intervention within 3 months prior to screening; CABG in past 3 months prior to screening, or current indication for coronary revascularization.
  2. Cardiac resynchronization therapy initiated within 3 months prior to enrollment.
  3. Advanced heart failure defined as one or more of the following:

    1. ACC/AHA/ESC Stage D HF or non-ambulatory Class IV HF.
    2. Inotropic infusion (continuous or intermittent) within 6 months prior to screening.
    3. Subject is on the cardiac transplant waiting list or has undergone transplant.
    4. Presence of, or history of, mechanical circulatory support for HF.
    5. Planned other advanced HF Therapies in the next 12 months.
  4. Right heart dysfunction defined as tricuspid annular plane systolic excursion (TAPSE) \<12 mm or right ventricular (RV) fractional area change (FAC) \<25% (at screening visit and determined by echo core lab).
  5. (BMI) >45 kg/m2.
  6. 6-minute walk test distance \<100 meters OR >450 meters.
  7. Admission for HF within the 30 days prior to planned index procedure.
  8. Any known history of orthostatic hypotension or orthostatic hypotension at the time of screening (regardless of the presence of symptoms). Orthostatic hypotension is defined as a systolic blood pressure (BP) decrease of >20 mmHg upon going from supine to standing position or undergoing treatment with Midodrine.
  9. Orthostatic pulse pressure narrowing from supine to standing (+3 minutes) of ≥10mmHg in the absence of a HR increase >15bpm
  10. Postural orthostatic tachycardia syndrome or preload insufficiency syndrome or on medical therapy for neurogenic orthostatic hypotension (e.g., midodrine, droxidopa).
  11. Systolic BP \<100 mmHg or >170 mmHg despite appropriate medical management.
  12. Baseline screening resting HR >100 beats per minute or ventricular tachycardia.
  13. Catheter ablation for atrial fibrillation within 6 months prior to screening or planned in the next 12 months at the time of screening.
  14. Presence of significant valve disease defined by the site cardiologist as:

    1. Greater than mild mitral valve stenosis.
    2. Greater than moderate mitral valve regurgitation.
    3. Greater than moderate-to-severe tricuspid valve regurgitation.
    4. Greater than moderate aortic valve stenosis or regurgitation.
  15. Any planned procedure to address valve disease in the past 6 months.
  16. Known hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or other infiltrative cardiomyopathy (e.g., hemochromatosis, sarcoidosis).
  17. History of liver cirrhosis.
  18. Prior weight loss surgery
  19. Dialysis dependent; or estimated \<20 ml/min/1.73 m2 by CKD-EPI creatinine equation.
  20. Arterial oxygen saturation \<90% on room air.
  21. Chronic pulmonary disease requiring continuous home oxygen OR hospitalization for exacerbation of chronic pulmonary disease (including intubation) in the 12 months before study entry OR known history of GOLD Class III or worse (COPD).
  22. Participating in conflicting drug or device study that is not completed within 30 days prior to the screening visit.
  23. \<12 months for non-cardiovascular reasons.
  24. Any condition, or history of illness or surgery that, in the opinion of the site investigator or Screening Committee, might confound the results of the study or pose additional risks to the patient.
  25. Females who are pregnant or lactating or planning to become pregnant during the next year.
  26. LVEDD > 7.5 cm (at screening visit and determined by echo core lab)
  27. Estimated peak pulmonary artery pressure (PAP) > 70 mmHg (at screening visit and determined by echo core lab).

    Exclusion Criteria Assessed During the index procedure:

  28. Vessel tortuosity or variant vascular anatomy that could preclude the access or maneuvering of the interventional device from the access site to target vessel. This includes previous spine surgery that may impact the ability to access and treat the target sites of T11 and T10.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Greater Splanchnic Nerve Ablation

    Subjects receive catheter-based unilateral ablation of the right greater splanchnic nerve (GSN) using the Satera Ablation System. Randomization occurs during the procedure after anesthesia or sedation and after confirmation that the subject's vein anatomy is suitable for treatment.

    Device: Right Greater Splanchnic Nerve (GSN) ablation

  • Sham comparator
    Sham treatment

    Subjects undergo a simulated procedure designed to mimic the treatment experience without delivering nerve ablation. This includes venous access via a small needle puncture in the groin or neck and assessment of vein anatomy, but no treatment catheter is inserted and no ablation is performed. The sham procedure lasts approximately the same amount of time as the active treatment.

    Procedure: Sham Control

Interventions

  • DeviceRight Greater Splanchnic Nerve (GSN) ablation

    Subjects receive catheter-based unilateral ablation of the right greater splanchnic nerve.

  • ProcedureSham Control

    Simulated procedure designed to mimic the treatment experience without delivering nerve ablation

06

What researchers measure

Primary outcomes

  1. Device or procedure related serious adverse events

    Evaluation of device or procedure related serious adverse events based on Clinical Events Committee (CEC) assessment

    Time frame: Treatment through the 1 month

  2. NT-proBNP (6 months)

    Assessment of change in NT-ProBNP from baseline to 6-month follow up visit

    Time frame: Baseline through the 6 months

Secondary outcomes

  1. Serious device related cardiac or vascular events

    Incidence of serious device related cardiac or vascular events for up to 12 months

    Time frame: Treatment through the 12 months

  2. Device or procedure related pain

    Device or procedure related pain lasting at least 30 days and requiring medical management

    Time frame: Enrollment through the 12 months

  3. Orthostatic hypotension

    Incidence of new orthostatic hypotension up to 12 months

    Time frame: Procedure through 12 months

  4. Acute Kidney Injury

    Incidence of AKI requiring renal replacement therapy up to 12 months

    Time frame: Procedure through 12 months

  5. Worsening Glomerular Filtration Rate (GFR)

    Incidence of worsening GFR (defined as change \> 50% for at least 30 days in duration) up to 12 months

    Time frame: Procedure through 12 months

  6. Adverse Events

    Incidence of all Adverse Events through 12 months

    Time frame: Procedure through 12 months

  7. Mortality

    Incidence of all mortality for up to 12 months summarized as all-cause mortality, CV mortality, or heart failure-related

    Time frame: Procedure through 12 months

  8. Left Ventricular End Diastolic Volume (LVEDV)

    Change in LVEDV from baseline indexed for body surface area (LVEDVi ml/m2) at 6 and 12 month follow up

    Time frame: Baseline through 6- and 12- months

  9. Left Ventricular Ejection Fraction (LVEF)

    Change in LVEF from baseline at 6 and 12 month follow up

    Time frame: Baseline through 6- and 12-months

  10. NT-proBNP (12 months)

    Change in NT-proBNP evaluated over time from baseline through 12 months

    Time frame: Baseline through 12 months

  11. Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Change in KCCQ scores evaluated over time from baseline through 6 and 12 months

    Time frame: Baseline through 6- and 12-months

  12. 6-minute Walk Test (6MWT)

    Change in 6MWT evaluated over time from baseline through 6 and 12 months

    Time frame: Baseline through 6- and 12-months

  13. Worsening Heart Failure (Time to)

    Time to first heart failure hospitalization or worsening heart failure event through 6 and 12 months

    Time frame: Baseline through 6- and 12-months

  14. Worsening Heart Failure (Incidence)

    Incidence of heart failure hospitalization and worsening heart failure events through 6 and 12 months

    Time frame: Baseline through 6- and 12-months

  15. Composite Endpoint

    Hierarchical composite endpoint of cardiovascular death, heart failure events, and changes from baseline to 12 months in KCCQ OSS

    Time frame: Baseline through 12 months

Other outcomes

  1. Diuretic Dose

    Change in diuretic dose through 6 and 12 months

    Time frame: Baseline through 6- and 12 months

  2. High Sensitivity C-reactive Protein

    Change in high sensitivity C-reactive protein levels from baseline through 6 and 12 months

    Time frame: Baseline through 6- and 12 months

  3. Weight

    Change in weight from baseline through 6 and 12 months

    Time frame: Baseline through 6- and 12 months

  4. HbA1c

    Change in HbA1c from baseline through 6 and 12 months

    Time frame: Baseline through 6- and 12 months

  5. Technical Success (Primary) - treatment cohort only

    Technical success of RF ablation of the GSN at the T11 level, defined as successful catheter positioning at the target site, completion of RF energy delivery, and absence of device-related Serious Adverse Events.

    Time frame: Procedure

  6. Technical Success (Secondary) - treatment cohort only

    Technical success (Secondary) of RF ablation of the GSN at the T10 level, defined as successful catheter positioning at the target site, completion of RF energy delivery, and absence of device-related Serious Adverse Events.

    Time frame: Procedure

  7. SGLT2 Inhibitor Dose

    Number of changes in SGLT2 Inhibitor dose and percentage of subjects with at least one change through 6- and 12-months

    Time frame: Baseline through 6- and 12-months

  8. Angiotensin Receptor Blocker (ARB) Dose

    Number of changes in Angiotensin Receptor Blocker Dose and percentage of subjects with at least one change though 6- and 12-months

    Time frame: Baseline through 6- and 12-months

  9. ACE Inhibitor Dose

    Number of subjects with changes in ACE Inhibitor Dose and percentage of subjects with at least one change through 6- and 12-months

    Time frame: Baseline through 6- and 12-months

  10. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Dose

    Number of subjects with changes in Angiotensin Receptor-Neprilysin Inhibitor dose and percentage of subjects with at least one change through 6- and 12-months

    Time frame: Baseline through 6- and 12-months

  11. Aldosterone Antagonist (MRA) Dose

    Number of subjects with changes in Aldosterone Antagonist (MRA) Dose and percentage of subjects with at least one change through 6- and 12-months

    Time frame: Baseline through 6- and 12-months

  12. Beta Blocker Dose

    Number of subjects with changes in Beta Blocker dose and percentage of subjects with at least one change through 6- and 12-months

    Time frame: Baseline through 6- and 12-months

  13. Aldosterone (ALD)

    Change in aldosterone levels from baseline through 6- and 12-months

    Time frame: Baseline through 6- and 12-months

  14. Renin

    Change in Renin levels from Baseline through 6- and 12-months

    Time frame: Baseline through 6- and 12-months

07

Study locations

7 of 9 sites recruiting
08

References and documents

Publications

  • Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999 Jun 15;18(11):1341-54. doi: 10.1002/(sici)1097-0258(19990615)18:113.0.co;2-7. PubMed 10399200 ↗
  • Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012 Jan;33(2):176-82. doi: 10.1093/eurheartj/ehr352. Epub 2011 Sep 6. PubMed 21900289 ↗
  • Fudim M, Fail PS, Litwin SE, Shaburishvili T, Goyal P, Hummel SL, Borlaug BA, Mohan RC, Patel RB, Mitter SS, Klein L, Rocha-Singh K, Patel MR, Reddy VY, Burkhoff D, Shah SJ. Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE-HF trial roll-in cohort. Eur J Heart Fail. 2022 Aug;24(8):1410-1414. doi: 10.1002/ejhf.2559. Epub 2022 May 29. PubMed 35598154 ↗
  • Fudim M, Patel MR, Boortz-Marx R, Borlaug BA, DeVore AD, Ganesh A, Green CL, Lopes RD, Mentz RJ, Patel CB, Rogers JG, Felker GM, Hernandez AF, Sunagawa K, Burkhoff D. Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. JACC Heart Fail. 2021 Apr;9(4):293-300. doi: 10.1016/j.jchf.2020.12.006. Epub 2021 Mar 10. PubMed 33714749 ↗
  • Malek F, Gajewski P, Zymlinski R, Janczak D, Chabowski M, Fudim M, Martinca T, Neuzil P, Biegus J, Mates M, Kruger A, Skalsky I, Bapna A, Engelman ZJ, Ponikowski PP. Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first-in-human clinical trial. Eur J Heart Fail. 2021 Jul;23(7):1134-1143. doi: 10.1002/ejhf.2209. Epub 2021 Jul 16. PubMed 33932262 ↗
  • Maher JW, Johlin FC, Pearson D. Thoracoscopic splanchnicectomy for chronic pancreatitis pain. Surgery. 1996 Oct;120(4):603-9; discussion 609-10. doi: 10.1016/s0039-6060(96)80006-7. PubMed 8862367 ↗
  • Fudim M, Boortz-Marx RL, Ganesh A, DeVore AD, Patel CB, Rogers JG, Coburn A, Johnson I, Paul A, Coyne BJ, Rao SV, Gutierrez JA, Kiefer TL, Kong DF, Green CL, Jones WS, Felker GM, Hernandez AF, Patel MR. Splanchnic Nerve Block for Chronic Heart Failure. JACC Heart Fail. 2020 Sep;8(9):742-752. doi: 10.1016/j.jchf.2020.04.010. Epub 2020 Jun 10. PubMed 32535123 ↗
  • Fudim M, Jones WS, Boortz-Marx RL, Ganesh A, Green CL, Hernandez AF, Patel MR. Splanchnic Nerve Block for Acute Heart Failure. Circulation. 2018 Aug 28;138(9):951-953. doi: 10.1161/CIRCULATIONAHA.118.035260. No abstract available. PubMed 29804067 ↗
  • Baghdadi S, Abbas MH, Albouz F, Ammori BJ. Systematic review of the role of thoracoscopic splanchnicectomy in palliating the pain of patients with chronic pancreatitis. Surg Endosc. 2008 Mar;22(3):580-8. doi: 10.1007/s00464-007-9730-x. Epub 2007 Dec 28. PubMed 18163168 ↗
  • RAPAPORT E, WEISBART MH, LEVINE M. The splanchnic blood volume in congestive heart failure. Circulation. 1958 Oct;18(4 Part 1):581-7. doi: 10.1161/01.cir.18.4.581. No abstract available. PubMed 13573575 ↗
  • Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010 Sep;3(5):588-95. doi: 10.1161/CIRCHEARTFAILURE.109.930701. Epub 2010 Jun 11. PubMed 20543134 ↗
  • Burkhoff D, Tyberg JV. Why does pulmonary venous pressure rise after onset of LV dysfunction: a theoretical analysis. Am J Physiol. 1993 Nov;265(5 Pt 2):H1819-28. doi: 10.1152/ajpheart.1993.265.5.H1819. PubMed 8238596 ↗
  • Funakoshi K, Hosokawa K, Kishi T, Ide T, Sunagawa K. Striking volume intolerance is induced by mimicking arterial baroreflex failure in normal left ventricular function. J Card Fail. 2014 Jan;20(1):53-9. doi: 10.1016/j.cardfail.2013.11.007. Epub 2013 Nov 28. PubMed 24291683 ↗
  • Barnes RJ, Bower EA, Rink TJ. Haemodynamic responses to stimulation of the splanchnic and cardiac sympathetic nerves in the anaesthetized cat. J Physiol. 1986 Sep;378:417-36. doi: 10.1113/jphysiol.1986.sp016228. PubMed 3795110 ↗
  • Fudim M, Ganesh A, Green C, Jones WS, Blazing MA, DeVore AD, Felker GM, Kiefer TL, Kong DF, Boortz-Marx RL, Hernandez AF, Patel MR. Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. Eur Heart J. 2018 Dec 21;39(48):4255-4256. doi: 10.1093/eurheartj/ehy682. No abstract available. PubMed 30346508 ↗
  • Brooksby GA, Donald DE. Dynamic changes in splanchnic blood flow and blood volume in dogs during activation of sympathetic nerves. Circ Res. 1971 Sep;29(3):227-38. doi: 10.1161/01.res.29.3.227. No abstract available. PubMed 5093284 ↗
  • Greenway CV. Role of splanchnic venous system in overall cardiovascular homeostasis. Fed Proc. 1983 Apr;42(6):1678-84. PubMed 6832386 ↗
  • CHIEN S. Cell volume, plasma volume and cell percentage in splanchnic circulation of splenectomized dogs. Circ Res. 1963 Jan;12:22-8. doi: 10.1161/01.res.12.1.22. No abstract available. PubMed 14020808 ↗
  • DELORME EJ, MacPHERSON AI, MUKHERJEE SR, ROWLANDS S. Measurement of the visceral blood volume in dogs. Q J Exp Physiol Cogn Med Sci. 1951;36(4):219-31. doi: 10.1113/expphysiol.1951.sp000975. No abstract available. PubMed 14892239 ↗
  • Greenway CV, Lister GE. Capacitance effects and blood reservoir function in the splanchnic vascular bed during non-hypotensive haemorrhage and blood volume expansion in anaesthetized cats. J Physiol. 1974 Mar;237(2):279-94. doi: 10.1113/jphysiol.1974.sp010482. PubMed 4825450 ↗
  • Gelman S. Venous function and central venous pressure: a physiologic story. Anesthesiology. 2008 Apr;108(4):735-48. doi: 10.1097/ALN.0b013e3181672607. PubMed 18362606 ↗
  • Fudim M, Kaye DM, Borlaug BA, Shah SJ, Rich S, Kapur NK, Costanzo MR, Brener MI, Sunagawa K, Burkhoff D. Venous Tone and Stressed Blood Volume in Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol. 2022 May 10;79(18):1858-1869. doi: 10.1016/j.jacc.2022.02.050. PubMed 35512865 ↗
  • Sorimachi H, Burkhoff D, Verbrugge FH, Omote K, Obokata M, Reddy YNV, Takahashi N, Sunagawa K, Borlaug BA. Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction. Eur J Heart Fail. 2021 Oct;23(10):1648-1658. doi: 10.1002/ejhf.2254. Epub 2021 Jun 17. PubMed 34053158 ↗
  • Fudim M, Hernandez AF, Felker GM. Role of Volume Redistribution in the Congestion of Heart Failure. J Am Heart Assoc. 2017 Aug 17;6(8):e006817. doi: 10.1161/JAHA.117.006817. No abstract available. PubMed 28862947 ↗
  • Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, Lund LH. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018 Sep;20(9):1326-1334. doi: 10.1002/ejhf.1182. Epub 2018 Mar 26. PubMed 29578280 ↗
  • Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodegard J, Lund LH, Thuresson M, Bozkurt B. Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC Heart Fail. 2023 Jan;11(1):1-14. doi: 10.1016/j.jchf.2022.08.009. Epub 2022 Sep 7. PubMed 36202739 ↗
  • Lund LH, Crespo-Leiro MG, Laroche C, Zaliaduonyte D, Saad AM, Fonseca C, Celutkiene J, Zdravkovic M, Bielecka-Dabrowa AM, Agostoni P, Xuereb RG, Neronova KV, Lelonek M, Cavusoglu Y, Gellen B, Abdelhamid M, Hammoudi N, Anker SD, Chioncel O, Filippatos G, Lainscak M, McDonagh TA, Mebazaa A, Piepoli M, Ruschitzka F, Seferovic PM, Savarese G, Metra M, Rosano GMC, Maggioni AP; ESC EORP HF III National Leaders and Investigators. Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry. Eur J Heart Fail. 2024 Dec;26(12):2487-2501. doi: 10.1002/ejhf.3445. Epub 2024 Sep 10. PubMed 39257278 ↗
  • Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020 Jul 11;396(10244):121-128. doi: 10.1016/S0140-6736(20)30748-0. Epub 2020 May 21. PubMed 32446323 ↗
  • Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail. 2011 Sep;4(5):669-75. doi: 10.1161/CIRCHEARTFAILURE.111.961789. No abstract available. PubMed 21934091 ↗
  • Adamson PB, Magalski A, Braunschweig F, Bohm M, Reynolds D, Steinhaus D, Luby A, Linde C, Ryden L, Cremers B, Takle T, Bennett T. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003 Feb 19;41(4):565-71. doi: 10.1016/s0735-1097(02)02896-6. PubMed 12598066 ↗
  • Nijst P, Verbrugge FH, Bertrand PB, Martens P, Dupont M, Drieskens O, Penders J, Tang WH, Mullens W. Plasma Volume Is Normal but Heterogeneously Distributed, and True Anemia Is Highly Prevalent in Patients With Stable Heart Failure. J Card Fail. 2017 Feb;23(2):138-144. doi: 10.1016/j.cardfail.2016.08.008. Epub 2016 Aug 22. PubMed 27561853 ↗
  • Miller WL. Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed. Circ Heart Fail. 2016 Aug;9(8):e002922. doi: 10.1161/CIRCHEARTFAILURE.115.002922. PubMed 27436837 ↗
  • Androne AS, Hryniewicz K, Hudaihed A, Mancini D, Lamanca J, Katz SD. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol. 2004 May 15;93(10):1254-9. doi: 10.1016/j.amjcard.2004.01.070. PubMed 15135699 ↗
  • Ambrosy AP, Cerbin LP, Armstrong PW, Butler J, Coles A, DeVore AD, Dunlap ME, Ezekowitz JA, Felker GM, Fudim M, Greene SJ, Hernandez AF, O'Connor CM, Schulte P, Starling RC, Teerlink JR, Voors AA, Mentz RJ. Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. JACC Heart Fail. 2017 Jan;5(1):1-13. doi: 10.1016/j.jchf.2016.09.012. PubMed 28034373 ↗
  • Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, Aranda JM Jr, Abraham WT, Smart FW, Stevenson LW, Kueffer FJ, Bourge RC. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008 Sep 30;118(14):1433-41. doi: 10.1161/CIRCULATIONAHA.108.783910. Epub 2008 Sep 15. PubMed 18794390 ↗
  • Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM. Patterns of weight change preceding hospitalization for heart failure. Circulation. 2007 Oct 2;116(14):1549-54. doi: 10.1161/CIRCULATIONAHA.107.690768. Epub 2007 Sep 10. PubMed 17846286 ↗
  • Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, Giannetti N, Grzeslo A, Hamilton PG, Heckman GA, Howlett JG, Koshman SL, Lepage S, McKelvie RS, Moe GW, Rajda M, Swiggum E, Virani SA, Zieroth S, Al-Hesayen A, Cohen-Solal A, D'Astous M, De S, Estrella-Holder E, Fremes S, Green L, Haddad H, Harkness K, Hernandez AF, Kouz S, LeBlanc MH, Masoudi FA, Ross HJ, Roussin A, Sussex B. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017 Nov;33(11):1342-1433. doi: 10.1016/j.cjca.2017.08.022. Epub 2017 Sep 6. PubMed 29111106 ↗
  • Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul 20;355(3):251-9. doi: 10.1056/NEJMoa052256. PubMed 16855265 ↗
  • Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011 Jan;13(1):18-28. doi: 10.1093/eurjhf/hfq121. Epub 2010 Aug 3. PubMed 20685685 ↗
  • Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1. PubMed 35363499 ↗
  • Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004-2016. BMC Cardiovasc Disord. 2018 May 2;18(1):74. doi: 10.1186/s12872-018-0815-3. PubMed 29716540 ↗
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-3639. doi: 10.1093/eurheartj/ehad195. No abstract available. PubMed 37622666 ↗
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20. No abstract available. PubMed 27207191 ↗
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available. PubMed 34447992 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2028, 20 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 20 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Jun 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 11, 2026
StartActual
Jun 12, 2026was Mar 2026
Primary completionEst.
Mar 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
3 sites added — first site in Georgia. 6 sites changed recruiting status (4 now recruiting, 2 now not yet recruiting)
Show 6 sites
  • Motol and Homolka University Hospital · Prague, Czechiano status→Recruiting
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wrocławiu · Wroclaw, Polandno status→Not yet recruiting
  • Hospital Clínico Universitario de Valencia-INCLIVA · Valencia, Spainno status→Recruiting
  • Vithas Valencia Turia · Valencia, Spainno status→Recruiting
  • Leeds General Infirmary · Leeds, United Kingdomno status→Not yet recruiting
  • King's College London · London, United Kingdomno status→Recruiting
Show 3 added (2 Georgia, 1 Spain)
  • Heart and Vascular Clinic · Tbilisi, Georgia
  • Tbilisi Heart Center · Tbilisi, Georgia
  • Hospital Universitari Quirónsalud Barcelona · Barcelona, Spain
Nov 6, 2026
Start date
Mar 1, 2026→Jun 12, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    3 sites added — first site in Georgia. 6 sites changed recruiting status (4 now recruiting, 2 now not yet recruiting)
    Show 6 sites
    • Motol and Homolka University Hospital · Prague, Czechiano status→Recruiting
    • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wrocławiu · Wroclaw, Polandno status→Not yet recruiting
    • Hospital Clínico Universitario de Valencia-INCLIVA · Valencia, Spainno status→Recruiting
    • Vithas Valencia Turia · Valencia, Spainno status→Recruiting
    • Leeds General Infirmary · Leeds, United Kingdomno status→Not yet recruiting
    • King's College London · London, United Kingdomno status→Recruiting
    Show 3 added (2 Georgia, 1 Spain)
    • Heart and Vascular Clinic · Tbilisi, Georgia
    • Tbilisi Heart Center · Tbilisi, Georgia
    • Hospital Universitari Quirónsalud Barcelona · Barcelona, Spain
    Start date Mar 1, 2026→Jun 12, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07403058
Lead sponsor
Axon Therapies, Inc.
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Jun 12, 2026
Primary completion
Mar 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Judit Adorjan
Contact
j.adorjan@axontherapies.com
+1 650 722-1119
Piotr Ponikowski, MD, PhD
principal investigator · Professor of Cardiology, Head of the Department of Heart Diseases at Wroclaw Medical University
Marat Fudim, MD, MHS
principal investigator · Associate Professor of Medicine, Duke Clinical Research Institute of Cardiology
Klaus Witte, MD
principal investigator · Senior Lecturer in Cardiology and Consultant Cardiologist Leeds Institute of Cardiovascular and Metabolic Medicine University of Leeds and Leeds Teaching Hospitals NHS Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion